Understanding deprescribing of preventive cardiovascular medication: a Q-methodology study in patients

Clare H Luymes,1 Nelleke J Boelhouwer,1 Rosalinde KE Poortvliet,1 Wouter de Ruijter,1 Ria Reis,1–3 Mattijs E Numans1 1Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, 2Amsterdam Institute for Social Science Research, University of Amsterdam, Amsterda...

Full description

Bibliographic Details
Main Authors: Luymes CH, Boelhouwer NJ, Poortvliet RKE, de Ruijter W, Reis R, Numans ME
Format: Article
Language:English
Published: Dove Medical Press 2017-05-01
Series:Patient Preference and Adherence
Subjects:
Online Access:https://www.dovepress.com/understanding-deprescribing-of-preventive-cardiovascular-medication-a--peer-reviewed-article-PPA
id doaj-b780b0ede06a45ea8f7eed35de168cc6
record_format Article
spelling doaj-b780b0ede06a45ea8f7eed35de168cc62020-11-24T23:38:18ZengDove Medical PressPatient Preference and Adherence1177-889X2017-05-01Volume 1197598432993Understanding deprescribing of preventive cardiovascular medication: a Q-methodology study in patientsLuymes CHBoelhouwer NJPoortvliet RKEde Ruijter WReis RNumans MEClare H Luymes,1 Nelleke J Boelhouwer,1 Rosalinde KE Poortvliet,1 Wouter de Ruijter,1 Ria Reis,1–3 Mattijs E Numans1 1Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, 2Amsterdam Institute for Social Science Research, University of Amsterdam, Amsterdam, the Netherlands; 3The Children’s Institute, University of Cape Town, Cape Town, South Africa Background: Patients with low cardiovascular disease (CVD) risk potentially use preventive cardiovascular medication unnecessarily. Our aim was to identify various viewpoints and beliefs concerning the preventive CVD management of patients with low CVD risk using preventive cardiovascular medication. Furthermore, we investigated whether certain viewpoints were related to a preference for deprescription or the continuation of preventive cardiovascular medication.Methods: In 2015, we purposively sampled patients from the intervention arm of the Evaluating Cessation of STatins and Antihypertensive Treatment In primary Care (ECSTATIC) trial in the Netherlands for this study. Participants made Q-sorts by ranking 43 statements concerning preventive CVD management from “totally disagree” to “totally agree”. These Q-sorts were analyzed using PQMethod 2.35 software. A varimax procedure presented the distinguishing viewpoints that were favored by our participants. We used group discussion quotations to underline our findings. For validation purposes, we asked participants how well each viewpoint fitted them.Results: Of 291 invited patients, 33 participated. Thirty-one Q-sorts were analyzed. The following three viewpoints were found: 1) a controlling viewpoint, in which patients held the belief that monitoring blood pressure and cholesterol levels is important (n=13, of which seven had their medication deprescribed and six continued their medication); 2) an autonomous viewpoint, in which patients showed a dislike of medication (n=8, of which seven had their medication deprescribed and one had it continued); and 3) an afraid viewpoint, in which patients were fearful of developing CVD (n=8, of which two had their medication deprescribed and six had it continued). Seventy-four percent of the participants believed that the viewpoint to which they were assigned was a good fit.Conclusion: Three well-discriminating viewpoints about preventive CVD management were determined. Knowing and recognizing these viewpoints is effective for general practitioners when discussing the deprescribing of preventive cardiovascular medications with patients and may be used to promote implementation of deprescription. Keywords: general practice, preventive medicine, cardiovascular diseases, antihypertensive agents, anticholesteremic agents, inappropriate prescribinghttps://www.dovepress.com/understanding-deprescribing-of-preventive-cardiovascular-medication-a--peer-reviewed-article-PPAGeneral PracticePreventive MedicineCardiovascular DiseasesAntihypertensive AgentsAnticholesteremic AgentsInappropriate Prescribing
collection DOAJ
language English
format Article
sources DOAJ
author Luymes CH
Boelhouwer NJ
Poortvliet RKE
de Ruijter W
Reis R
Numans ME
spellingShingle Luymes CH
Boelhouwer NJ
Poortvliet RKE
de Ruijter W
Reis R
Numans ME
Understanding deprescribing of preventive cardiovascular medication: a Q-methodology study in patients
Patient Preference and Adherence
General Practice
Preventive Medicine
Cardiovascular Diseases
Antihypertensive Agents
Anticholesteremic Agents
Inappropriate Prescribing
author_facet Luymes CH
Boelhouwer NJ
Poortvliet RKE
de Ruijter W
Reis R
Numans ME
author_sort Luymes CH
title Understanding deprescribing of preventive cardiovascular medication: a Q-methodology study in patients
title_short Understanding deprescribing of preventive cardiovascular medication: a Q-methodology study in patients
title_full Understanding deprescribing of preventive cardiovascular medication: a Q-methodology study in patients
title_fullStr Understanding deprescribing of preventive cardiovascular medication: a Q-methodology study in patients
title_full_unstemmed Understanding deprescribing of preventive cardiovascular medication: a Q-methodology study in patients
title_sort understanding deprescribing of preventive cardiovascular medication: a q-methodology study in patients
publisher Dove Medical Press
series Patient Preference and Adherence
issn 1177-889X
publishDate 2017-05-01
description Clare H Luymes,1 Nelleke J Boelhouwer,1 Rosalinde KE Poortvliet,1 Wouter de Ruijter,1 Ria Reis,1–3 Mattijs E Numans1 1Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, 2Amsterdam Institute for Social Science Research, University of Amsterdam, Amsterdam, the Netherlands; 3The Children’s Institute, University of Cape Town, Cape Town, South Africa Background: Patients with low cardiovascular disease (CVD) risk potentially use preventive cardiovascular medication unnecessarily. Our aim was to identify various viewpoints and beliefs concerning the preventive CVD management of patients with low CVD risk using preventive cardiovascular medication. Furthermore, we investigated whether certain viewpoints were related to a preference for deprescription or the continuation of preventive cardiovascular medication.Methods: In 2015, we purposively sampled patients from the intervention arm of the Evaluating Cessation of STatins and Antihypertensive Treatment In primary Care (ECSTATIC) trial in the Netherlands for this study. Participants made Q-sorts by ranking 43 statements concerning preventive CVD management from “totally disagree” to “totally agree”. These Q-sorts were analyzed using PQMethod 2.35 software. A varimax procedure presented the distinguishing viewpoints that were favored by our participants. We used group discussion quotations to underline our findings. For validation purposes, we asked participants how well each viewpoint fitted them.Results: Of 291 invited patients, 33 participated. Thirty-one Q-sorts were analyzed. The following three viewpoints were found: 1) a controlling viewpoint, in which patients held the belief that monitoring blood pressure and cholesterol levels is important (n=13, of which seven had their medication deprescribed and six continued their medication); 2) an autonomous viewpoint, in which patients showed a dislike of medication (n=8, of which seven had their medication deprescribed and one had it continued); and 3) an afraid viewpoint, in which patients were fearful of developing CVD (n=8, of which two had their medication deprescribed and six had it continued). Seventy-four percent of the participants believed that the viewpoint to which they were assigned was a good fit.Conclusion: Three well-discriminating viewpoints about preventive CVD management were determined. Knowing and recognizing these viewpoints is effective for general practitioners when discussing the deprescribing of preventive cardiovascular medications with patients and may be used to promote implementation of deprescription. Keywords: general practice, preventive medicine, cardiovascular diseases, antihypertensive agents, anticholesteremic agents, inappropriate prescribing
topic General Practice
Preventive Medicine
Cardiovascular Diseases
Antihypertensive Agents
Anticholesteremic Agents
Inappropriate Prescribing
url https://www.dovepress.com/understanding-deprescribing-of-preventive-cardiovascular-medication-a--peer-reviewed-article-PPA
work_keys_str_mv AT luymesch understandingdeprescribingofpreventivecardiovascularmedicationaqmethodologystudyinpatients
AT boelhouwernj understandingdeprescribingofpreventivecardiovascularmedicationaqmethodologystudyinpatients
AT poortvlietrke understandingdeprescribingofpreventivecardiovascularmedicationaqmethodologystudyinpatients
AT deruijterw understandingdeprescribingofpreventivecardiovascularmedicationaqmethodologystudyinpatients
AT reisr understandingdeprescribingofpreventivecardiovascularmedicationaqmethodologystudyinpatients
AT numansme understandingdeprescribingofpreventivecardiovascularmedicationaqmethodologystudyinpatients
_version_ 1725517069825343488